Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Light Sciences Oncology Inc.

Apr 2007
Light Sciences Oncology Inc. of Seattle has made an agreement with the FDA on a special protocol assessment for a Phase III clinical trial. This will allow the company to compare its light infusion therapy product with another treatment for metastatic colorectal cancer in the liver. The device provides photodynamic therapy, by using LEDs to activate talaporfin sodium. Through production of singlet oxygenmolecules, the light-activated drug induces apoptosis in cells within a defined zone around the LED array.

Biophotonicsenergylight infusionLight Sciences Oncology Inc.light sourcesNews & FeaturesLEDs

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.